Stilla Technologies is a multiplex digital PCR company that focuses on accelerating development of next-generation genetic testing.
Stilla is taking digital PCR to a whole new level with a unique 6-color target detection capability.
Stilla Technologies was co-founded in 2013 by Rémi Dangla. The company is headquartered in Villejuif, France, with an office in Beverly, Massachusetts.
Stilla is transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing.
Stilla’s groundbreaking Crystal Digital PCR™ solution, the naica® system, is the industry’s first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market.
Stilla actively advises and supports its customers worldwide through its dynamic and multidisciplinary R&D team, with expertise spanning from microfluidics to chemistry, including molecular biology and AI.
Stilla is backed by Casdin Capital, European Investment Bank (EIB), Illumina Ventures, Kurma Partners, TusPark Capital Management, LBO France, BNP Paribas Developpement, Eurazeo, and others. The company raised €31.3M in new financing on Nov 24, 2021. This brings Stilla's total funding to €67.5M to date.